- Home
- BHVN
BHVN
Biohaven Ltd.
as 12-20-2024 4:00pm EST
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 3.6B | IPO Year: | 2017 |
| Target Price: | $63.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.80 - $62.21 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 197.10% |
Stock Insider Trading Activity of Biohaven Ltd. (BHVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Coric Vlad | BHVN | Chief Executive Officer | Oct 2 '24 | Buy | $47.50 | 21,052 | $999,970.00 | 861,942 | |
| CHILDS JOHN W | BHVN | Director | Oct 2 '24 | Buy | $47.50 | 21,052 | $999,970.00 | 21,052 | |
| Bailey Gregory | BHVN | Director | Sep 24 '24 | Buy | $44.19 | 5,000 | $220,966.00 | 1,620,071 |
Latest Biohaven Ltd. News
BHVN Breaking Stock News: Dive into BHVN Ticker-Specific Updates for Smart Investing
Benzinga
4 days ago
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
Insider Monkey
5 days ago
Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
PR Newswire
6 days ago
Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates
PR Newswire
16 days ago
Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting
Benzinga
a month ago
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study
PR Newswire
a month ago
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
PR Newswire
a month ago
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments
Investor's Business Daily
2 months ago
Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy
Compare BHVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BHVN Biohaven Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.